Stanford University
Showing 181-190 of 617 Results
-
Daniel Aaron Gerber, MD
Clinical Associate Professor, Medicine - Cardiovascular Medicine
BioDr. Gerber is a critical care cardiologist and medical director of Stanford's cardiac ICU. He has dual subspecialty training in cardiovascular and critical care medicine and additional board certification in echocardiography. He completed his residency in internal medicine, fellowship in cardiovascular medicine, and an additional fellowship in critical care medicine at Stanford University and joined as faculty in 2021 as a Clinical Assistant Professor in the Department of Medicine’s Division of Cardiovascular Medicine.
Dr. Gerber manages the full spectrum of heart and vascular conditions with a focus on critically ill patients with life-threatening cardiovascular disease. He is active in medical education, teaching introductory echocardiography to Stanford medical students and residents, co-directing the Stanford Critical Care Medicine Critical Care Ultrasound Program, and lecturing nationally on critical care echocardiography and point-of-care ultrasonography at the Society of Critical Care Medicine’s annual congress. Finally, Dr. Gerber’s research interests focus on optimizing cardiac intensive care, including working with the Critical Care Cardiology Trials Network (CCCTN) - a national network of tertiary cardiac ICUs coordinated by the TIMI Study Group - and studying acute mechanical circulatory support techniques to improve patient outcomes and care processes. -
Yael Gernez
Clinical Associate Professor, Pediatrics - Immunology
BioMy clinic focuses on solving the molecular puzzles that underlie rare allergic and immunologic diseases to shed light on fundamental principles governing allergy, inflammation and immune system defects. My goal is to find better and safer therapies for my patients with rare diseases that include autoinflammation, autoimmunity and primary immune deficiency. It is important to highlight that every patient requires individualized therapeutic approaches based on their underlying genetic problem and the types and severity of their clinical manifestations. For some patients, a hematopoietic stem cell transplant (HSCT) is curative while for others, a targeted drug therapy, such as a biologic or small molecule agent, is most suitable. In some cases, a truly novel therapy may be required, .e.g., anti-sense oligonucleotide therapy to suppress aberrant gene splicing or adoptive cellular therapy. My passion is to provide the best personalized therapy for our patients with allergy and immunology diseases. This often requires performing very specialized functional assays and in some cases in enlisting laboratories with specific expertise or interest in particular genetic disorders.
-
Rabin Gerrah
Clinical Assistant Professor, Cardiothoracic Surgery
BioDr. Rabin Gerrah is a cardiothoracic surgeon and specializes in surgical treatment of heart diseases such as ischemic, valvular, structural and congenital heart diseases. He has been trained at Harvard University and Columbia University Hospitals. Dr. Gerrah has been involved in multiple medical research projects and has patented and developed innovative surgical devices and technologies.
-
Elias Roth Gerrick
Member, Maternal & Child Health Research Institute (MCHRI)
BioEli received his B.S. in Microbiology and Immunology from U.C. Irvine in 2013, where he worked in the lab of Dr. Celia Goulding. He earned his Ph.D. from Harvard University in 2018 in the lab of Dr. Sarah Fortune, where he studied post-transcriptional regulation of gene expression in Mycobacterium tuberculosis. Eli joined the Howitt lab at Stanford in the summer of 2018, where he is studying the influence of protozoan members of the microbiome on intestinal immunity.
